Clinical Trials
4 trialsNCT03656536 2025-08-24
FIGHT-302
Incyte Corporation
Phase 3 Terminated
NCT02924376 2025-08-14
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Incyte Corporation
Phase 2 Completed
NCT04256980 2024-05-30
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Completed
NCT02393248 2023-01-06
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
Phase 1/2 Terminated